Paolini John F. 4

What Happened

• John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals (KNSA), exercised stock options and sold the resulting shares on May 1, 2026. He acquired 58,424 shares by exercising options at $10.36 per share (cost $605,273), and sold a total of 58,424 shares in two open‑market transactions for approximately $3,137,823 (proceeds: $1,997,741 and $1,140,082). The Form 4 also reports a derivative disposition of 58,424 shares at $0.00 on the same date. Sales were effected under a prearranged Rule 10b5‑1 plan.

Key Details

• Transaction date: 2026-05-01; Form 4 filed 2026-05-05 (covers the May 1 transactions).
• Option exercise (code M, acquired): 58,424 shares at $10.36, total $605,273.
• Open‑market sales (code S, disposed): 37,327 shares at a weighted avg $53.52 (proceeds $1,997,741); 21,097 shares at a weighted avg $54.04 (proceeds $1,140,082). Combined sale proceeds ≈ $3,137,823.
• Derivative disposition (code M, disposed): 58,424 shares reported at $0.00 in the filing.
• Footnotes: F1—sales were made pursuant to a Rule 10b5‑1 plan adopted Nov 18, 2025; F2/F3—sales executed in multiple trades with price ranges (weighted averages reported); F4—the option was fully vested and exercisable.
• Shares owned after the reported transactions are not disclosed in the provided filing.

Context

• This sequence (exercise of options followed by same‑day sales) is consistent with a cashless exercise / sell‑to‑cover pattern and is common for executives exercising vested options. Because the sales were executed under a Rule 10b5‑1 plan, they were prearranged and do not necessarily reflect a change in the insider’s view of the company. The filing is informational and factual; it does not state the insider’s motivation.